Michael Thomas Henderson - 22 Jun 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Director
Issuer ticker: SYRE
Reported as of: 22 Jun 2026
Net transaction value: -$2,000,000
SEC form: 4
Accepted by SEC: 23 Jun 2026, 21:32:23 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Michael Thomas Henderson filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 23 Jun 2026.

Key facts

This page summarizes Michael Thomas Henderson's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 21:32.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: -$2,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001779990 Primary reporting owner

HENDERSON MICHAEL THOMAS

Relationship: Director
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Sale

Transaction value: $2,000,000
Shares: -20,000
Change %: -23%
Price: $100.00
Shares after: 68,606
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.